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ABSTRACT
Activation of the tumour suppressor p53 on DNA
damage involves post-translational modification by
phosphorylation and acetylation. Phosphorylation
of certain residues is critical for p53 stabilization
and plays an important role in DNA-binding activity.
The 14-3-3 family of proteins activates the DNA-
binding affinity of p53 upon stress by binding to a
site in its intrinsically disordered C-terminal domain
containing a phosphorylated serine at 378. We have
screened various p53C-terminal phosphorylated
peptides for binding to two different isoforms of
14-3-3, e and c. We found that phosphorylation
at either S366 or T387 caused even tighter binding
to 14-3-3. We made by semi-synthesis a tetrameric
construct comprised of the tetramerization plus
C-terminal domains of p53 that was phosphorylated
on S366, S378 and T387. It bound 10 times tighter
than did the monomeric counterpart to dimeric
14-3-3. We showed indirectly from binding curves
and directly from fluorescence-detection analytical
ultracentrifugation that 14-3-3 enhanced the binding
of sequence-specific DNA to p53 by causing p53
dimers to form tetramers at lower concentrations.
If the in vitro data extrapolate to in vivo, then it is
an attractive hypothesis that p53 activity may be
subject to control by accessory proteins lowering
its tetramer–dimer dissociation constant from its
normal value of 120–150 nM.
p53, as a transcription factor, exerts its tumour suppres-
sor function by the downstream expression of various
target genes including those involved in either cell-cycle
arrest or apoptosis (1–4). p53 levels are low in normal
unstressed cells, but rise upon stress stimuli. Various
post-translational modiﬁcations of p53, such as acetyla-
tion and phosphorylation, are early events upon stress
that activate p53 to the functional active form. p53 is
phosphorylated at multiple sites upon DNA damage,
with the pattern depending on the nature of the stress
stimulus. The N-terminus of p53 is multiply phosphory-
lated at sites that include S6, S9, S15, S18, S20, S33, S37,
S46, T55 and T81. Phosphorylation at S15 and S20 dis-
rupts its interaction with MDM2, the negative regulator of
p53, thereby leading to stabilization (5,6). Various kinases
are involved in these phosphorylations, with more than
one kinase for certain serine/threonine residues, suggesting
the importance of fail-safe mechanisms (7–9). Cell-cycle
checkpoint kinases 1 and 2 are involved in the phosphor-
ylation of S366, S378 and T387 of the C-terminal domain
(10). Despite this speciﬁc knowledge on phosphorylation
events, it is not yet fully clear how post-translational mod-
iﬁcations activate p53.
Phosphorylation of p53at S378 and dephosphorylation
at S376 create a 14-3-3-binding site and thereby increase
the sequence-speciﬁc DNA-binding aﬃnity of p53 (11).
The 14-3-3 family of proteins is involved in various cellular
signalling events.There arenine isoforms of 14-3-3 known in
mammals; a,b,g,d,e,Z,s,  and . The 14-3-3familybinds
to phosphoserine or phosphothreonine containing motifs
and regulates various cellular functions such as cell division,
nuclear transport, apoptosis or diﬀerentiation (12,13). The
protein 14-3-3 exists as a dimer with two binding pockets
for the phosphoserine containing motifs, as shown by the
crystalstructureof14-3-3boundtoaphosphoserinepeptide.
Two distinct 14-3-3 binding motifs, which are referred
to as mode 1 [R (S/Ar)XpS(LEAM)P] (13) and mode 2
[RX(Y/F)XpS(LEAM)P] binding motifs, were identiﬁed
using peptide libraries (14,15).
In the present study, we have screened the p53
C-terminal regulatory domains (p53CT) that are phos-
phorylated (Table 1) at various positions for binding to
two diﬀerent 14-3-3 isoforms, e and g, and measured the
binding aﬃnities for the various peptides using ﬂuorescence
anisotropy titration and equilibrium sedimentation experi-
ments (AUC). We also investigated how 14-3-3 inﬂuences
the sequence-speciﬁc binding of p53 to DNA using analyti-
cal ultracentrifugation (AUC) with ﬂuorescence detection.
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Proteinexpression andpurification
PET vectors encoding his6 tagged 14-3-3 e and g were
transformed into Escherichia coli BL21 for overexpres-
sion. Three litres of expression cultures at 378C and 250
r.p.m. were induced with 0.8mM IPTG at an A600 0.6
and allowed to express for 16h at 208C. The cells were
harvested by centrifugation followed by suspension in cell-
cracking buﬀer of 50mM sodium phosphate, pH 7.5,
300mM NaCl, 14mM b-mercaptoethanol and lysis by
sonication. After centrifugation, the soluble fraction was
loaded onto a Hi-trap Ni column and eluted with a
10–250mM imidazole gradient over 10-column volumes.
The pooled fractions were digested with TEV protease
overnight and then diluted with equilibration buﬀer
followed by loading onto the Ni column. The ﬂow-
through was concentrated and further puriﬁed on a Super-
dex 75 26/60 preparative gel ﬁltration column (Amersham
Biosciences, UK) in 20mM HEPES, 150mM NaCl, 5mM
DTT, 10% glycerol, pH 7.2. The proteins were >95%
pure as judged by SDS/polyacrylamide gel electrophoresis.
Protein samples were ﬂash frozen and stored in liquid
nitrogen for further use. The full-length p53 carrying sta-
bilizing mutations (16,17) was expressed and puriﬁed as
previously described (18).
Electrophoretic mobility shift assayexperiments
The electrophoretic mobility shift assay (EMSA) for ﬂp53
was carried out using p21 dsDNA (4mM) CGCGAAC
ATGTTCGAACATGTTCGCG labelled with ﬂuorescein
at 50-end. Phosphorylated p53 (8mM) was incubated with
various amounts of 14-3-3 for 1h followed by addition of
p21 DNA for 30min in 20mM HEPES, 150mM NaCl,
5mM DTT, 10% glycerol, pH 7.2. The reaction mixtures
were then separated on 0.8% agarose gel in 1X TBE for
3h at a rate of 5V/cm.
Fluorescence anisotropy and analyticalcentrifugation
All experiments were done as described (18–20). The
reported values are the means of three independent
experiments. Binding data from both the ﬂuorescence ani-
sotropy and the equilibrium sedimentation (where applic-
able) matched well. We used Aviv ﬂuorescence detection
system (FDS, Aviv Biomedical, NJ, USA) for the detec-
tion of ﬂuorescence signal from labelled protein mole-
cules and SedVel60K-FDS ﬂuorescence velocity cells
(Spin Analytical, Inc, Durham, NH, USA) with sample
volumes of 65ml. Buﬀer conditions were 25mM sodium
phosphate, 150mM NaCl, 5mM DTT, pH 7.2, 10% glyc-
erol, 0.2mg/ml BSA. The samples contained full-length
p53at concentration of 12.5–100 nM. Data were analysed
using SedFit software (21).
Phosphorylation of recombinant p53 and purification
The puriﬁed recombinant p53 was phosphorylated using
CHKI and CHKII as guided by the supplier (New England
Biolabs, UK) and as described (10). Phosphorylation was
followed by mass spectrometry. After 2–3h of reaction,
the reaction mixture was loaded onto a Superdex 200
26/10 analytical gel ﬁltration column to separate the phos-
phorylated p53 from the reaction cocktail and eluted in
20mM HEPES, 150mM NaCl, 5mM DTT, 10% glycerol,
pH 7.2. The phosphorylated p53 was used for the EMSA
experiments.
Peptide synthesis and purification
Peptides were synthesized on a Pioneer peptide synthesizer
(Applied Biosystems, UK) using standard Fmoc chemistry.
Phosphorylated serine and threonine were incorporated into
thepeptidesduringsolidphasepeptidesynthesisusingFmoc-
Ser(PO(Obzl)OH)-OH and Fmoc-Thr(PO(Obzl)OH)-OH
(Nova biochem). S362C introduced at the N-terminus of
the peptide was used for either coupling to the ﬂuorescein
50-maleimide or for the semi-synthetic ligation. The peptides
were puriﬁed on a Waters HPLC using a reverse phase C18
and C8 semipreparative column (Vydac) and a acetonitrile
gradient in water as described (19).
RESULTS
Screening of C-terminal phosphopeptides for14-3-3 binding
p53 does not contain any of the deﬁned mode 1
(RSXpSXP) or mode 2 (RXXXpSXP) 14-3-3-binding
motifs. However, the 14-3-3 family of proteins binds to
various targets with signiﬁcant deviation from the canoni-
cal sequences. We screened various p53CT phosphopep-
tides (362–393) for 14-3-3 binding. Table 2 lists the various
monophosphorylated peptides screened with two of the
14-3-3 isoforms; g and e. Wild-type p53CT peptide did
not show any detectable binding. Three peptides with
phosphorylation at S366, S378 and T387 had dissociation
constants of 14, 17 and 20mM, respectively, with 14-3-3g
as measured by ﬂuorescence anisotropy and AUC.
Figure 1 shows the anisotropy curves for the three phos-
phopeptides pS366, pS378 and pT387 with 14-3-3g. Two
other isoforms of 14-3-3, e and s, were tested for binding.
Table 1. Peptides used for screening
Peptides Sequence
a
pS314 KRALPNNTSSSPQPKKKPLDG
pS315 KRALPNNTSSSPQPKKKPLDG
WT CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS366 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS376 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS378 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pT387 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS392 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS366/pT387 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS378/pT387 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
pS366/pS378 CRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
Mode 2
binding peptide
ARLYHSLLPAA
aPeptides were labelled using ﬂuorescein 50-maleimide at the cysteine
introduced in the p53CT peptides. pS314, pS315, mode 2 binding
peptide and all the p53TCT were labelled using ﬂuorescein succinimidyl
ester at the free amino end of the peptides. S and T indicate
phosphorylated serine and threonine, respectively.
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as did the g-isoform. It is reported, from immunopre-
cipitation and western blot assays, that 14-3-3 binds to
pS378 (14). We also tested two peptides NLS (Nuclear
Localization Signal, 305–322) derived from the tetramer-
ization domain of p53 with phosphorylations at residues
314 and 315. pS314 showed weak binding, and pS315 did
not show any binding at all to either of 14-3-3 isoforms.
14-3-3binds strongly todiphosphorylated peptides
In solution, 14-3-3 exists as a dimer and each 14-3-3 dimer
possesses two binding pockets for phosphoserine or
phosphothreonine ligands (Figure 2). The 14-3-3 binds
with higher aﬃnity to phosphopeptides containing two
14-3-3-binding sites separated by a spacer than to the
single-binding motif peptide (14). Our initial experiments
showed three essential phosphorylations for strong 14-3-3
binding. Hence, we synthesized three peptides carrying
diﬀerent combinations of the two phosphorylations:
pS366/pS378, pS378/pT387 and pS366/pT387. Each pep-
tide was tested for 14-3-3 binding (Figure 3). 14-3-3 bound
to the diphosphorylated peptides much more strongly
than to the monophosphorylated ones. Stoichiometric
titration was carried out to ﬁnd out how many 14-3-3
molecules bind to a single peptide. The sharp transition
point from unbound to bound species gives the stoichio-
metry of binding at high concentration of the peptide
when titrated with 14-3-3. One 14-3-3 dimer bound one
doubly phosphorylated peptide (Figure 3C). Table 3 lists
the binding data for the peptides obtained using ﬂuores-
cence anisotropy measurements. A peptide with a mode 2
binding motif was synthesized to compare the binding
aﬃnities of the various peptides. As can be seen from
the Table 3, the diphosphorylated peptide pS366/pT387
bound much more strongly than the consensus mode 2
peptide.
Tetrameric p53TCT bound10 times tighter thanmonomeric
p53CT peptides
Since p53 is tetrameric, we looked at 14-3-3 binding to
p53CT in the context of the tetramer. Five peptides
Table 2. Binding of mono-phosphorylated p53CT peptides (362–393)
to 14-3-3
Peptides Kd (mM)
14-3-3g 14-3-3e
pT387 14 3
a 11 2
a
pS366 17 2
a 16 2
a
pS378 20 2
a 18 3
a
pS392 105 6
b 134 8
b
pS376 225 20
b 175 10
b
pS314 130 7
b 158 8
b
pS315 No binding No binding
WT (362–393) Weak binding(n.q) Weak binding (n.q)
aMeasured using ﬂuorescence anisotropy and AUC ﬁtted to a simple
one-state model.
bMeasured using AUC only.
Peptides are labelled at the cysteine introduced using ﬂuorescein
50-maleimide; n.q, not quantiﬁable.
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Figure 1. Binding titration proﬁles of 14-3-3g with ﬂuorescein-labelled
monophosphorylated p53CT peptides. (A) 14-3-3g binding to pS366
and pT387 peptides. (B) 14-3-3g binding to pS378 peptide.
Experiments were conducted at 208C in 20mM HEPES, 150mM
NaCl, 5mM DTT, pH 7.2.
Figure 2. Structure of the 14-3-3/mode 2 phosphopeptide complex.
Each 14-3-3 monomer binds a monophosphorylated peptide (red)
(24). Peptides with diphosphorylations separated by a ﬂexible linker
bind with higher aﬃnity. This is observed in all of the p53CT diphos-
phorylated peptides.
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approach: three monophosphorylated peptides (pS366,
pS378 and pT387), a diphosphorylated peptide (pS366/
pT387) and the wild-type peptide. Table 4 lists the binding
data obtained for the tetrameric constructs. Tetrameric
p53TCT pS366, pS378, pT387 had Kd values of 1.8, 1.7
and 1.2mM, respectively, compared to 17, 14 and 20mM,
respectively, for the corresponding monomeric constructs.
Figure 4 shows the binding curves for the tetrameric con-
structs. Wild-type p53TCT (293–393) displayed very weak
binding while the diphosphorylated p53TCT only showed
similar binding to the monomeric diphosphorylated ones.
One reason for this apparent discrepancy may be that
14-3-3 binds to the diphosphorylated tetrameric p53 in a
more complex fashion, with a mixture of bound complexes
as opposed to the single complex formed between a mono-
phosphorylated binding motif and each 14-3-3 subunit.
14-3-3cincreases the sequence-specific DNA-binding
affinity ofp53
Binding of 14-3-3 enhances the sequence-speciﬁc DNA
binding of p53 (11). To investigate the mechanism of
enhancement, we carried out EMSA on binding to recom-
binant full-length p53 (ﬂp53) that is phosphorylated using
CHKI and CHKII kinases. In vitro phosphorylated
p53 was incubated with increasing amounts of 14-3-3 for
1h followed by addition of p53 recognition sequence
p21 labelled at the 50-end with ﬂuorescein for 30min.
Increasing amount of 14-3-3 enhanced the p53/DNA com-
plex formation (Figure 5A). Competition experiments
with unlabelled p21 and mutant p21 response element
showed the increase in binding is sequence speciﬁc
and the eﬀect was similar on diﬀerent lengths of DNA
Table 3. Binding of di-phosphorylated p53CT peptides (362–393)
to 14-3-3
Peptides Kd (nM)
14-3-3g 14-3-3e
Consensus 430 6
a 540 10
a
pS366/pT387 140 7
a 180 5
a
pS366/pS378 480 5
a 512 3
a
pS378/pT387 450 3
a 805 6
a
aMeasured using ﬂuorescence anisotropy only.
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Figure 3. Binding isotherms of 14-3-3g with ﬂuorescein-labelled p53CT
diphosphorylated peptides. (A) 14-3-3g binding to p53CT diphospho-
peptides, pS366/pT387, pS366/pS378 and pS378/pT387. (B) Binding of
14-3-3g to the mode 1 consensus peptide. (C) Stoichiometric titration of
14-3-3g with pS366/pT387 peptide revealed that one 14-3-3 dimer binds
one diphosphorylated peptide.
Table 4. Binding oftetrameric p53TCTwithmono- ordi-phosphorylated
subunits (293–393) to 14-3-3
Peptides Kd
a (mM)
14-3-3g 14-3-3e
WT TC (293–393) Weak binding Weak binding
p53TCT pS366 3 0.5 6.2 0.6
p53TCT pT387 1.2 0.5 3.5 0.8
p53TCT pS378 1.7 0.3 1.4 0.5
p53TCTS366/pT387 0.154 0.004 0.310 0.008
aMeasured using ﬂuorescence anisotropy only. Peptide concentrations
used for titrations were 0.7mM.
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cence anisotropy titrations of phosphorylated ﬂp53 bind-
ing to ﬂuorescein-labelled p21 response element DNA
gave a Hill constant of  2.1 and half saturation at
45nM. The Hill constant dropped to  1.1 with a Kd of
22nM on titrating with the ﬂp53/14-3-3 complex
(Figure 5B and C). The observed binding is not the non-
speciﬁc binding of DNA to the C terminus as that mode
has a dissociation constant of 6–8mM (22).
Measuringthedissociationconstantoffull-lengthp53byAUC
To delineate the mechanism of 14-3-3-mediated speciﬁc-
DNA binding of p53, we employed an AUC method
with ﬂuorescence detection measuring sedimentation
velocities. A tetracysteine (TC) motif was introduced to
the C terminus of p53, which was site-speciﬁcally labelled
with a FlAsH dye. The biarsenical-labelling reagent
FlAsH-EDT2 becomes ﬂuorescent when it binds to pro-
teins containing the TC motif Cys-Cys-Pro-Gly-Cys-Cys.
Introducing the dye did not aﬀect 14-3-3 binding to p53.
p53 existed as a tetramer at as low as 600 nM (expressed
in monomer concentrations). Dimers and tetramers of p53
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Figure 4. Fluorescence anisotropy titrations of 14-3-3g with tetrameric
P53CT-phosphorylated peptides (p53TCT). (A) Binding of 14-3-3g to
ﬂuoresceinated p53TCT pS366, pS378 and pT387 peptides. (B) Binding
of 14-3-3g to p53TCT pS366/pT387 peptide. Concentration of peptide
used was 0.7mM to ensure that p53TCT was tetrameric under experi-
mental conditions.
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Figure 5. DNA-binding experiments on p53. (A) EMSA experiments
show speciﬁc DNA-binding enhancement in the presence of 14-3-3g.
Lane 1: only DNA (4mM), lanes 2–8: phosphorylated p53 (8mM),
DNA (4mM) and increasing amounts of 14-3-3g (0, 2, 4, 8, 10, 15
and 20mM, respectively). (B and C) Three independent binding experi-
ments of p53 to p21 DNA labelled with ﬂuorescein at the 50-end in the
absence and presence of 5mM of 14-3-3, respectively. The data upon
ﬁtting to the Hill equation, [Protein]
h/(K
h+[Protein]
h), gave Hill
constants, h, of 2.1 and 1.1, respectively. The binding curve obtained
in the presence of 14-3-3 can be ﬁtted to a simple one-state binding
model [Protein]/(K+[Protein]), showing the non-cooperativity in
DNA binding of p53.
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500 nM. The dissociation constant for ﬂp53 was estimated
to be  120 nM from the integral of the area under the
distributions. At 50 nM, the major species observed is the
p53 dimer. When 1mM of 14-3-3 was added to 50nM
of phosphorylated ﬂp53, the low Mr peak disappeared
and a new peak emerged at Mr  285kDa, a diﬀerence
of 115kDa from the tetrameric p53, suggesting that
two dimers of 14-3-3 bound a p53 tetramer (Figure 6).
The stoichiometry was calculated from the diﬀerences
in the apparent molecular masses obtained by the ﬁt
and hence may not reﬂect the true complex.
DISCUSSION
Twopotential bindingsites for14-3-3 in p53CT domain
We screened a p53C-terminal phosphopeptide library
for potential 14-3-3 binding candidates (Table 1). Three
peptides phosphorylated at either S366, S378 or T387
bound with 14–20mM dissociation constants (Table 2).
Of these, only S378 was previously shown to bind
14-3-3. The Kd values obtained for the S366 and T387
phosphorylated peptides were lower than that for S378,
suggesting that these residues may also be involved in
14-3-3 recognition. S392 phosphorylation is important
for regulating the oncogenic function of mutant p53
(23). The binding of the S392 phosphorylated peptide to
14-3-3 was very weak as indicated by AUC. Wild-type
p53CT terminus peptide did not have detectable binding
up to 200mM.
Comparison ofmono-, di- and tetrameric p53TCT
peptides for14-3-3 binding
14-3-3 is a dimeric protein, with two binding pockets for
phosphopeptide motifs. A peptide with two tandem phos-
phoserine motifs separated by a spacer binds 14-3-3 much
more strongly than the isolated motifs (14). Peptides with
two phosphorylated sites, pS366/pS378, pS366/pT387 and
pS378/pT387 had 50–100 times higher aﬃnities than any
of the monophosphorylated peptides, suggesting that
14-3-3 binds as a dimer to the bi-phospho motifs that
are separated by a spacer (Table 3). The pS366/pT387
peptide bound much more tightly than did the other
diphosphorylated peptides, suggesting that the length of
the spacer may play some role in the binding events in the
context of 14-3-3. Since p53CT is unstructured and ﬂex-
ible, it can bind 14-3-3 in an extended conformation, like
many other interacting partners reported (15,24).
Since p53 functions as tetramer in binding response ele-
ments, we examined the binding aﬃnities of 14-3-3 to a
tetrameric construct of the p53CT, p53TCT. We made
four p53TCT constructs with monophosphorylation at
either S366, S378 or T387, and one diphosphorylation at
S366 and T387. The three monophosphorylated p53TCT
constructs had  10-fold higher aﬃnity than did the cor-
responding monomeric peptides, whereas the p53TCT
S366/T387 construct had a similar binding aﬃnity to its
equivalent monomeric peptide.
p53/14-3-3 complex binds DNA less cooperatively
by perturbing theoligomerization equilibrium
14-3-3 increases the sequence-speciﬁc binding aﬃnity of
DNA to the core domain of p53 through its association
to p53 (11), as conﬁrmed here by EMSA experiments on
phosphorylated ﬂp53 with increasing amounts of 14-3-3.
p53 exists as a dimer of dimers in solution. Two dimers of
p53 bind DNA cooperatively with a Hill constant of 2
(25). p53 assembles as a tetramer on DNA. The dissocia-
tion constant of tetrameric ﬂp53 to dimers is 120 30 nM,
from AUC experiments.
ﬂp53 that was phosphorylated at various residues, par-
ticularly S366, S378 and T387 were used for DNA-binding
experiments in the presence of 14-3-3. The ﬂp53/14-3-3
complex bound DNA less cooperatively than did ﬂp53
alone. The binding isotherms (Figure 5) ﬁtted well to a
simple one-state binding model or a cooperative Hill
model of low cooperativity with h close to 1, at 1.1. As
the cooperativity of binding of ﬂp53 to response ele-
ment DNA is caused by a unbound dimeric state going
to a bound tetramer, we tested the eﬀects of 14-3-3 on the
tetramerization of ﬂp53. At concentrations where ﬂp53 is
predominantly dimeric, p53 became a tetramer in the pre-
sence of 14-3-3 (Figure 6). Two dimers of 14-3-3 formed a
complex with tetrameric ﬂp53 (Figure 7). This is diﬀerent
from C-terminal peptides in isolation, where one diphos-
phorylated peptide binds one 14-3-3 dimer. In the context
of the full-length tetramer with multiple phosphory-
lations, there is a preferential binding mode in which
the phosphate-binding pockets in the two subunits of
the 14-3-3 homodimer are occupied by phosphoserine/
threonine residues from two diﬀerent subunits of the p53
tetramer, resulting in the observed p53/14-3-3 complex.
The oligomerization state of p53 ismodulated through
its interaction withbinding partnerproteins
Tetramerization of p53 is important for its activity.
S100 proteins are upregulated in cancer tissues and are
associated with stimulation of metastasis. The S100
family of proteins regulate the oligomerization of p53.
S100B and S100A bind to the tetramerizaton domain of
p53 only in lower oligomerization states presumably the
monomeric and the dimeric forms, in turn regulating the
subcellular localization of p53 (20). Apoptosis repressor
with caspase recruitment domain (ARC) is induced in
many cancer tissues. ARC inactivates p53 by binding to
the tetramerization domain of p53 (26). Both S100A and
ARC negatively regulate the activity of p53 by inhibiting
tetramerization and aﬀecting nuclear localization.
Another family of proteins, 14-3-3, positively regulates
the function of p53 by enhancing the oligomerization of
p53. The transcriptional activity of p53 is dependent on its
DNA-binding ability. Though the core domains of p53
can alone bind DNA, tetrameric p53 binds DNA coopera-
tively with enhanced aﬃnity. 14-3-3s was shown to
increase the transcriptional activity of p53 by facilitating
the oligomerization of p53. Also, binding of 14-3-3s
increases the stability of p53 by inhibiting the MDM2-
mediated ubiquitination of p53 (27).
5988 Nucleic Acids Research, 2008, Vol. 36, No. 18Here, we provide direct evidence for the inﬂuence of
14-3-3 on the DNA binding of p53 by enhancing its
oligomerization in vitro. Although neither the phosphor-
ylation status of S373 and S375 (equivalent to human
S376 and S378) nor 14-3-3 binding are critical for mouse
p53 function, these events play an important role in acti-
vating human p53 (28). There is no direct evidence in vivo
showing the activation of p53 by the modulation of its
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Figure 6. AUC experiments of FlAsH tagged full-length p53. (A) Fluorescence sedimentation proﬁles were acquired for the ﬂp53at 45 000 r.p.m.
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Nucleic Acids Research, 2008, Vol. 36, No. 18 5989oligomeric state. However, if the dissociation constant
of p53 from tetramers into dimers measured in vitro
holds good for in vivo, it is expected that p53 exists pre-
dominantly in dimeric form at lower concentrations.
Accordingly, it is an attractive hypothesis that the activity
of p53 may be up-regulated by its interaction with acces-
sory proteins that facilitate its tetramerization into the
form that binds response elements.
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